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Recent Strategies in 
Resveratrol Delivery Systems 
Noelia D. Machado,[a,b] Mariana A. Fernández[a,b] 
and David Díaz Díaz*[c, d] 
Abstract: Resveratrol, a natural polyphenolic stilbenoid widely 
found in grapes and wines, displays beneficial properties such 
as cardio protective, antioxidant and anti-inflammatory activities. 
The trans-resveratrol (RSV) is the most bioactive and more 
abundant stereoisomer found in nature. Despite the positive 
properties of RSV, there are various factors that limit its 
effectiveness, including low aqueous solubility, low oral 
bioavailability and chemical instability. During the last years, an 
increasing number of strategies such as nano and micro 
encapsulation have been developed in order to overcome these 
limitations and enhance the use of RSV in nutritional and 
pharmaceutical applications. This review summarizes the 
advances and main properties of several RSV carriers and 
delivery systems reported during the last 5 years. 
1. Introduction 
Resveratrol (3,5,4´-trihydroxy-stilbene) is a natural polyphenolic 
compound belonging to stilbene family that it is normally found in 
seeds, wines and skin of grapes, soybeans, cherrys, nuts and 
pomegranates.[1] The trans-resveratrol (RSV) is the most active 
and more abundant stereoisomer found in nature (Figure 1).  
 The interest of scientists in the utilization of this 
nutraceutical[2] compound has gradually increased during the last 
years due to apparent beneficial effects in human health, 
including anticancer, cardio protective, antioxidant and anti- 
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inflammatory activities, among others.[3] Although it is present  
in several foods, its systemic absorption in the organism is 
rather limited; being absorbed less than 1 % of consumed RSV. 
[
4
] The main factors that limit the RSV effectiveness are its low 
aqueous solubility (< 0.05 mg/mL) [1], low oral availability, and 
chemical instability. The diminished oral bioavailability is due to 
the susceptibility to suffer sulfatation and glucuronidation during 
the phase II of metabolism in the gastrointestinal tract. [5]  
 
Figure. 1 Trans-to-cis photoisomerization of RSV under UV irradiation. 
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 Furthermore, the trans-to-cis photoisomerization of RSV 
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is isomerized when it is exposed to sunlight, white light of high 
intensity, or ultraviolet light (Figure 1).[ 6 , 7 ] In addition, high 
temperatures,[8] pH changes [9,10] and some enzymes, [11,12] also 
promote chemical degradation of RSV.  
The mentioned factors limit a greater use of RSV in food 
and pharmaceutical industries,[13] motivating worldwide research 
to overcome the aforementioned disadvantages. Thus, during 
the last decade, numerous research groups have developed and 
explore potential solutions based on nano and 
microencapsulation technologies. Within this context, several 
carriers based mainly on emulsions, particles, gels, nanocrystals 
and vesicles have been developed. The aim of this review is to 
provide an overview of the last improvements obtained in the 
formulation of RSV for different applications. The review is 
focused on the results published during the last five years, 
complementing previous revisions[3,13,14,15]. In addition, we also 
provide a supplementary table (see ESI) that compiles all the 
chemical structures of the compounds mentioned in the text, 
which offers a quick visual insight about the molecular structures 
of the components used to prepare the delivery vehicles. 
2. Delivery systems 
2.1. Vesicles 
2.1.1. Niosomes 
Among different carriers, liposomes and niosomes are well-
documented drug delivery systems. Niosomes are vesicles 
consisting of an aqueous core enclosed within a non-ionic 
surfactant bilayer. Structurally, they are similar to liposomes and 
posses similar physical properties, so they have been proposed 
as a stable and less expensive alternative version of those. 
Following, we will describe some recent applications of 
niosomes as RSV carriers. 
 In 2015, Pando and co-workers designed niosomal 
formulations loaded with RSV for topical use.[16] The niosomes 
were prepared using Gelot 64 (G64) as surfactant and oleic 
(OA) or linoleic acids as stabilizers. In addition, these fatty acids 
are known as skin penetration enhancers. Different 
surfactant:stabilizer weight ratios were studied in the range of 
1:0.5–1:1.5, with the RSV concentration  adjusted to 1 g/L. The 
niosomes were prepared using the thin film hydration (TFH) 
combined with sonication and ethanol injection method (EIM). In 
both methods, niosomes were spherical in shape, albeit those 
obtained via EIM were in the range 299–402 nm and showed 
polidispersity indexes (PDI < 0.3). On the other hand, the TFH-
sonication method produced larger niosomes (ca. 293–496 nm) 
and with higher PDI indexes (< 0.4). Moreover, the RSV 
encapsulation efficiency (EE) obtained using EIM was higher 
than THF-sonication (e.g., for formulation G64-OA (1:1), EE = 35 
± 2 % and 24 ± 2 %, respectively. Finally, stability studies over 
time using G64/fatty acid (1:1) showed that EIM niosomes were 
more stable than TFH-sonication ones. The latter showed 
creaming phenomena with an increase of backscattering up to 
20 %. 
 In another example from the same group, Pando and co-
workers formulated RSV entrapped niosomes for oral 
administration. Niosomes were composed by Span 60 or 
Maisine 35–1 (Mai) as surfactants and dodecanol (Dod) as 
stabilizer. It was previously demonstrated, that fatty alcohols 
could also stabilize niosome membranes.[17] In this study, the 
RSV concentration in all formulations was adjusted to 0.15 g/L. 
Niosomes were prepared using a TFH-sonication method. 
Among different agitation speeds and surfactant:Dod weight 
ratio, the optimal values to achieve the highest RSV EE were 
15000 rpm and a ratio Span 60:Dod/1:1.5 (w/w), respectively. In 
addition, the use of these parameters provided niosomes with 
the smallest mean diameter of 168 ±4 nm, a PDI of 0.247 ± 
0.018 and an EE of 64 ± 8 %. On the other hand, Mai:Dod/1:1.5 
(w/w) niosomes were obtained with a mean diameter of 175 ± 13 
nm, a PDI of 0.260 ± 0.025 and a RSV EE of 53 ± 8 %. Stability 
of niosomes was also determined by analyzing the ζ-potential 
over time. The results indicated that the formulation Span 
60:Dod/1:1.5 (w/w) were highly stable, with a ζ-potential value of 
(-50.1 ± 0.8) mV, confirming the absence of 
coagulation/flocculation processes due to the electrostatic 
repulsion effects among the niosomes. Interestingly, in spite of 
an observed creaming phenomenon, Mai:Dod/1:1.5 (w/w) 
niosomes exhibited acceptable stability with a ζ-potential value 
of –39.9 ± 0.3 mV. [18] 
 Additionally, Vankayala and co-workers prepared 
biocompatible RSV-loaded niosomes via sonication method 
using non-ionic surfactants and a fatty alcohol as stabilizer.[19] 
The formulation was prepared with Span 60 and cetyl alcohol in 
1:0.5 molar ratio. Niosomes were spherical and exhibited a 
smooth surface, characterized by 108 ± 3 nm particle size with a 
PDI of 0.24 ± 0.01, and –52.8 ± 0.6 mV of ζ-potential. The RSV 
EE in this system was 81 ± 2 %, being the encapsulation of RSV 
confirmed by Fourier-transform infrared spectroscopy (FT-IR) 
and differential scanning calorimetry (DSC) measurements. The 
amount of RSV encapsulated by this system was promising for 




Liposomes are the pioneer in vesicular systems to carry active 
principles. Differing from niosomes, liposomes are vesicles 
formed by phospholipids, which can include several other 
constituents like cholesterol to improve the stability of the bilayer. 
Caddeo and co-workers developed liposomes for topical delivery 
of RSV. Liposomes were made from Soy phosphatidylcholine 
and OA mixed with penetration enhancers (10:1:1 weight ratio), 
OramixTM CG110 (OrCG) and LauroglycolTM FCC (LauFCC). [20] 
These are dermo-compatible and solubilizing non-ionic 
surfactants. Liposomes were formed by hydration of the mixture 
with Tris Buffer at pH 7.4 and sonication at high intensity. 
Microscopy images showed small and spherical unilamellar 
vesicles coexisting with oligolamellar structures (Figure 2). RSV 
vesicles were ca. 90 nm in diameter and displayed a narrow size 
distribution (PDI ≤ 0.26 ± 0.02). The ζ-potential was large and 
negative, in the range of –28/–35 mV, due to the presence of OA, 
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repulsion. All vesicles presented good RSV EE (> 70 %). In 
addition, the results of aggregation efficiency indicated that 
approximately 70 % of phospholipids were assembled into 
vesicles. MTS cell proliferation assay using 3T3 fibroblasts cells 
showed quantitative cell viability after 24 h, indicating non-
cytotoxicity of liposomes formulations. The presence of RSV 
inside the vesicles was verified by 1H NMR using the RSV 
aromatic protons as reference. In contrast to RSV solution or 
RSV dispersed with empty vesicles (physical mixture), when 
RSV-loaded vesicles were used, the signals of aromatic protons 
became broader with lower intensity, which was attributed to the 
slower molecular motion of RSV inserted in the bilayer. 
 
 
Figure 2. TEM micrographs of RSV-loaded liposomes containing LauFCC (a 
penetration enhancer). Adapted with permission from ref. 20. Copyright 2015, 
Elsevier.  
 
 Another liposomal formulation coated with succinyl 
chitosan for oral delivery of RSV was also developed by Caddeo 
and co-workers.[21] Liposomes were made of soybean lecithin 
and OA (10:1 w/w), and 2 % w/w of RSV was added to form the 
corresponding loaded liposomes. Quercetin was coencapsulated 
with RSV (Figure 3). In this approach, sonication was employed 
to prepare the vesicles, and N-succinyl chitosan was used as 
protective shell of liposomes due to its pH response (0.5 % w/v). 
Regarding the physical chemical characterization, the coated 
liposomes were fairly spherical with a mean diameter of 82 ± 3 
nm, a PDI of 0.10 and negative ζ-potential of –41 ± 7 mV. In this 
system, RSV EE was 70 ± 5 %. Additionally, small angle X ray 
scattering experiments confirmed that neither the vesicle 
lamellar arrangement nor the thickness were altered significantly 
as a result of the modification with succinyl chitosan, thus 
confirming the formation of a protective shell. Furthermore, 
liposomes were stable when stored over two months at different 
temperatures showing no important variations in their physical 
chemical characteristics. Very interestingly, accelerated stability 
profiles showed that the presence of succinyl chitosan increased 
the physical stability of the formulation in comparison with 
conventional liposomes, which showed vesicle aggregation. 
The same authors reported later the preparation of 
polyethylene glycol (PEG)-modified liposomes for RSV delivery. 
[
22
] The liposomes were prepared by direct sonication of 
Phospholipon 90G aqueous dispersion in the presence of two 
PEG-surfactants, a tri-block polymer L64 (Pluronic® L64) and D-
α-tocopheryl polyethylene glycol 1000 succinate (TPGS). So-
prepared PEG-modified liposomes were spherical with 
predominant unilamellar morphology, a size of 86 ± 3 nm, good 
homogeneity (PDI 0.20 ± 0.03), and negative ζ-potential (–21 ± 
4 mV). In this case, the EE was ca. 95 %. Besides, a greater 
stability of the vesicles was observed after 2 months of storage 
at 25 °C with no signs of physical alteration. In contrast, 
conventional liposomes showed progressive aggregation and 
precipitation suggesting that PEG-surfactants improved the 
vesicles stability. 
In general, the above-described modified liposomal 
formulations showed great features in terms of EE and improved 
stability compared to conventional ones.  
 
 
Figure 3. Cryo-TEM images of A) quercetin and resveratrol co-loaded 
liposomes and B) succinyl-chitosan liposomes. Adapted with permission from 




2.2.1 Simple emulsions 
 
In general, emulsions are colloidal dispersions, typically formed 
from emulsifiers dispersed in oil, and water. These systems can 
be distinguished according to their particle radius. In the 
nanoemulsions, the particle size is smaller than 100 nm and 
particles higher than 100 nm are present in conventional 
emulsions. Oil-in-water (O/W) emulsions are formed by spherical 
lipid particles dispersed in an aqueous medium. These particles 
have a core-shell structure where the nucleus is formed by oil 
molecules and the hydrophobic chains of the surfactants (i.e. 
emulsifying agents). The polar layer, instead, is formed by the 
polar heads of the surfactants.[23] 
In this field of knowledge, Zhou and co-workers developed 
series of nanoemulsions with the aim to enhance the oral 
bioavailability of RSV using intestinal glucoronidation inhibitory 
excipients, i.e. Labrasol.[24] The oily phase was composed by 
soybean oil and the aqueous phase was formed by soy lecithin, 
Labrasol and water. In this case, 0.1 % of RSV was added in the 
oily phase affording spherical droplets of 132 ± 9 nm in diameter, 
a PDI of 0.18 ± 0.01, a ζ-potential of –49 ± 4 mV. Herein, RSV 
EE was estimated in 93 ± 2 %, and Labrasol-nanoemulsions 
showed good stability up to 1 month storage at ca. 4 °C and 
25 °C.  
Mucoadhesive nanoemulsions were developed by Nasr for 
co-encapsulating RSV and curcumin (CUR) for transnasal 
treatment of neurodegenerative disease.[25 ] The oily phase of 
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aqueous phase by 10 % of Cremophor® 40 as surfactant. 
Hyaluronic acid (HA) was incorporated in the aqueous phase at 
a concentration of 1.5 % v/v. This compound was selected as 
coated material to increase the stability and mucoadhesiveness 
of the formulation. RSV loaded nanoemulsions were formed 
using a concentration of 0.125 % w/v. The HA coated 
formulations were spherical with a particle size of 115.2 ± 0.2 nm 
(Figure 4), a ζ-potential value of –24 ± 2 mV and a PDI of 0.24 ± 
0.01. The HA coating significantly increased the particle size and 
the negative charge of the formulation. In addition, the pH of 
nanoemulsions ranged from 6.6–6.7 and HA coated 
nanoemulsion was able to enhance the mucoadhesive forces ca. 
6 times in comparison with uncoated ones. Importantly, the 
nanoemulsions were found to maintain their properties and 
resist aggregation after storage at 4 °C. Besides, the amount of 
RSV did not change significantly and the formulation preserved 
its anti-oxidant activity even after three months. 
 
 
Figure 4. TEM micrographs of nanoemulsions composed by Labrafac 
Lipophile and Cremophor RH 40 (10 % v/v). A) Uncoated nanoemulsions 
(magnification: 30000×), and B) 1.5 % v/v HA coated nanoemulsions 
(magnification: 50000×). Adapted with permission from ref. 25. Copyright 2016, 
Informa Pharmaceutical Science. 
 
In contrast, Fang and co-workers prepared a RSV delivery 
system based on emulsions to improve stability and water 
solubility of RSV.[26] The emulsion is formed by 2-hydroxypropyl-
β-cyclodextrin (2-HP-β-CD), phosphatidyl choline 60 and a 
solution of soybean phospholipiddipropylene glycol (15 % w/w). 
The RSV-emulsion formulation was prepared by high-pressure 
homogenization method using 3 % (w/w) of trans-RSV in a 
glycerin:water (8:2) mixture. Characterization analyses showed 
spherical particles with a mean diameter of 122 ± 1 nm and a 
PDI of 0.2. The ζ-potential value was –42 ± 1 mV and the 
formulation remained stable over 4 weeks without changes in 
size and PDI. The pH of emulsion formulation was 4.99 ± 0.03, 
which is similar to the pH of human skin. 
In another related work, Herneisey and co-workers 
developed a theranostic RSV-nanoemulsions containing two 
complementary imaging agents for anti-inflammatory 
diseases.[ 27 ]These emulsions were prepared with Pluronic® 
P105, Cremophor® EL and olive oil, and the RSV was 
incorporated as a solution in polyethylenglycol. The imaging 
agents used in this study were a near-infrared fluorescence 
imaging agent, 1,1-dioctadecyl-3,3,3’,3’-
tetramethylindotricarbocyanine iodide, and a 19F magnetic 
resonance imaging agent, perfluoropolyether (PFPE). The PFPE 
was the core material of nanoemulsions, it was surrounded by 
an organic phase that was capable of carrying RSV and the 
iodide agent. The mean diameter of the nanoemulsions was 155 
± 33 nm, with a ζ-potential of –13 ± 5 mV. Besides, the colloidal 
system remained stable during 348 days stored at 4, 25 and 
37 °C. Furthermore, no significant difference in RSV loading was 
found as consequence of PFPE coating (95 % vs. 93 % without 
PFPE coating). 
A different system was developed by Yen and co-workers, 
who used a self-nanoemulsifying drug delivery system 
(SNEDDS) for RSV.[28] The optimized SNEDDS were composed 
of Capryol™ 90 as the oil phase, Cremophor® EL and Tween 20 
as surfactants (60:35:5 % w/w/w). In this case, the average 
particle size was ca. 41 ± 4 nm with a PDI of 0.4 ± 0.1 (Figure 5). 
 
 
Figure 5. RSV self-nanoemulsifying drug delivery system (RSV-SNEDDS) 
composed of Capryol™ 90, Cremophor® EL, Tween 20 (60:35:5 % w/w/w) 
dispersed in: A) water; and B) 0.1 N HCl; C) the appearance of RSV-
SNEDDS; and D) TEM micrograph of RSV-SNEDDS. Adapted with permission 
from ref. 28. Copyright 2017, MDPI. 
 
An alternative to this approach was reported by Mamadou 
and co-workers, who evaluated the capability of SNEDDS to 
enhance RSV permeation across rat intestine and modulate its 
presystemic metabolism.[ 29 ] The semi-solid nanoemulsions 
(semi-solid NE) were prepared with Gelucire® 44–14 and 
Labrasol, while liquid nanoemulsions (liquid-NE) were made 
using Miglyol® 812 and Tween 80. In both cases, a solution of 
0.9 mM of RSV was used to prepare loaded nanoemulsions. 
The semi-solid NE globule size was 21 ± 5 nm with a PDI of 0.36 
± 0.01 and a ζ-potential value of –15 ± 2 mV. The liquid-NE had 
a droplet size of 103 ± 14 nm, a PDI of 0.39 ± 0.05 and a ζ-
potential value of –15 ± 2 mV. 
In comparison, Yang and co-workers prepared a self-
microemulsifying drug delivery system (SMEDDS) with uridine-
5´-diphospho-glucuronosyltransferase (UGT) inhibitory 
excipients to increase the bioavailability of RSV by inhibiting 
intestinal metabolism.[ 30 ] SMEDDS delivery system was 
composed of Labrafil, Labrasol and Cremophor RH 40 as oil 
phase, surfactant and co-surfactants, respectively. 4 % w/w of 
RSV was added to produce loaded SMEDDS, which showed 
particles with a mean size of 26 ± 1 nm, a PDI value of 0.23 ± 
0.01 and a ζ-potential of –15 ± 3 mV. 
O/W emulsions stabilized by quinoa starch particles 
containing RSV were prepared by Matos and co-workers. 
Octenyl succinic anhydride (OSA) was used to increase the 
hydrophobicity of quinoa starch particles. The authors used 
Tween 20 to stabilize the emulsions and compare them with the 
effectiveness of starch as a stabilizer. To increase the solubility 
of RSV, the oil phase was composed of a mixture of Miglyol® 
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droplet size of 50 µm (Figure 6). However, RSV EE obtained for 
OSA-modified starch granules emulsions was 98 ± 2 %, while 
Tween 20 stabilized emulsions was 63 ± 1 %. As described by 
the authors, this could be explained due to RSV solubilization in 
the surfactant micelles in addition to oil droplets, similar results 
were also observed for other authors.[31] 
 
 
Figure 6. Microscope images of emulsions formulated with pure Miglyol 812 
as dispersed phase (A, B) and a mixture of Miglyol 812 and Orange oil (C, D) 
stabilized with Tween 20 (A, C) and OSA-modified Quinoa starch granules (B, 
D). Adapted with permission from ref. 32. Copyright 2018, Elsevier. 
 
Regarding the stability of the aforementioned emulsions, 
Tween 20 stabilized emulsions showed a clear migration of the 
drops toward the upper part of the cells without increase in 
droplet size within 1 h. On the other hand, starch emulsions also 
moved towards the upper part with no changes in drops size. 
However, the movement was in this case slower than in 
conventional emulsions, resulting in a more stable one. Authors 
explained this phenomenon because of the formation of heavier 
oil drops covered by starch particles than those covered by 
surfactant. Finally, rotational shear experiments of all samples 
showed a non-Newtonian behavior due to a marked dependency 
of the viscosity with shear rate.[32] 
In contrast, Dai and co-workers also designed a SNEDDS 
for RSV. The formulation was composed of sodium lignin 
sulfonate/Tween 80/PEG-400 as mixed surfactants and olive 
oil.[33] So-formed spherical particles were 119 ± 5 nm in diameter 
with a high ζ-potential value of –22 ± 1 mV. The stability of the 
formulations was evaluated by heating/cooling cycles. The 
results showed that lignin containing SNEDDS significantly 
increased the structural stability of trans-RSV, being the 
formulation clear, stable, with minor amount of RSV loss (< 2 %), 
and no phase separation even after 1 h under direct sunlight.  
 
2.2.2 Multiple emulsions 
 
Organized systems such as multiple emulsions of water-in-oil-in-
water (W/O/W) are small drops of water trapped within larger oil 
droplets that are dispersed in an aqueous medium.[34] In these 
systems, an oil-soluble emulsifier is usually employed to 
stabilize the internal water droplets, while a water-soluble 
emulsifier is used to stabilize the external droplets. 
Choi and co-workers formulated a RSV nutraceutical 
delivery system based on nanoemulsions.[ 35 ] Single-layer 
nanoemulsions were prepared by self-assembly emulsification 
method using water, medium-chain triacylglycerols as oily phase 
and Tween 80 as surfactant. The double-layer nanoemulsions 
were prepared adding 0.05 % w/v of charged polyelectrolytes 
(chitosan, alginate or β-cyclodextrin) onto the system made of 
single layer nanoemulsions. A RSV ethanolic solution (5 g/L) 
was used to prepare the loaded nanoemulsions. Single-
nanoemulsions showed a particle size of 27 ± 2 nm and a ζ-
potential value of –9 ± 1 mV. Moreover, double-nanoemulsions 
had average diameters of 27–55 nm depending on the 
polyelectrolyte used. The ζ-potential of double emulsions 
prepared with chitosan was 14 ± 4 mV due to the positive 
charge of chitosan molecules coated on the surface of 
nanoemulsions. On the other hand, ζ-potential of double 
emulsions prepared with alginate was –23 ± 1 mV due to the 
negative charge of the alginate molecules. In addition, ζ-
potential of double emulsions with β-cyclodextrin (β-CD) resulted 
in a stable negative value of –8 ± 1 mV. To confirm the stability 
of emulsions, their particle size and ζ-potential were evaluated 
for 28 days at 25 °C. In general, single and double 
nanoemulsions prepared with β-CD were more stable, whereas 
double nanoemulsions prepared with alginate and chitosan were 
unstable and showed slight increase in particle size in the same 
conditions. Furthermore, stability of RSV in nanoemulsions was 
determined during 7 storage days at 25 °C. The RSV content of 
double nanoemulsions prepared with β-CD was higher than in 
single-layer nanoemulsions, maintained ca. 95 % of RSV 
content until 6 days of storage. 
Food-grade double emulsion (W/O/W) containing RSV was 
prepared by Matos and co-workers using conventional and 
membrane emulsification (ME) methods.[36 ] The oily phase of 
these emulsions was composed by Miglyol® 812 containing 5 % 
(w/w) of polyglycerol polyricinoleate, a hydrophobic emulsifier. In 
this work, the inner aqueous phase (W) was composed either by 
20 % ethanol (v/v) or by a RSV solution (0.05 g/L) in the same 
medium. An electrolyte solution formed by 0.1 M NaCl was 
added to W to ensure inner droplets stability. Lastly, the external 
aqueous phase (W) was composed by 0.5 % (w/v) of 
carboxymethylcellulose, 2% (w/v) Tween 20, and 0.1 M NaCl to 
balance the osmotic pressure between the two aqueous phases. 
The best results considering size and distribution, rheological 
properties, RSV EE and stability, were obtained with ME (Figure 
7). In particular, RSV-containing emulsions showed a droplet 
size of 59.8 ± 0.2 µm and monodispersity (span values in the 
range 0.87–0.90). Rheological measurements indicated a 
Newtonian behavior with low elasticity and low viscosity values 
of ca. 5 mPa s. In addition, RSV EE in these emulsions was ca. 
55%. During the formulation storage, the release of RSV from 
these emulsions was very slow with variations of 2 %, 
suggesting that ME minimizes the drug loss owing to a 
homogeneous deposition of surfactant at the oil/water interface, 
which involves a higher barrier against diffusion. Stability 
measurements showed a slightly instability due to a clarification 
process as a result of oil droplets rise towards the top of the cell, 














This article is protected by copyright. All rights reserved.








Figure 7. Confocal image of W1/O/W2 emulsion containing RSV obtained with 
UV-vis lamp and prepared by ME. Adapted with permission from ref. 36. 
Copyright 2015, Elsevier. 
 
In comparison Acevedo-Fani and co-workers formulated 
another multiple emulsion containing RSV.[37] In this case, the 
single-layer emulsion was composed by lactoferrin and 
multilayer emulsion was formed by lactoferrin/alginate and 
lactoferrin/alginate/ε-poly-L-lysine (Figure 8). Multilayer 
emulsions were obtained by the electrostatic deposition of the 
biopolymers using a concentration of RSV of 0.002 % w/w. 
Primary emulsions with 1.90 % (w/w) of lactoferrin exhibited 
particles with an average diameter of 187 ± 4 nm, (PDI= 0.15 ± 
0.02) and a high positive ζ-potential value of 45.8 ± 0.5 mV. 
Moreover, secondary emulsions with 0.22 % w/w alginate, 
showed a droplet size of 249 nm and a very negative ζ-potential 
value (–54 mV). 0.036 % w/w of ε-poly-L-lysine was used to 
create a third interfacial layer around secondary emulsions. 
These emulsions showed a droplet size of 416 nm and a 
positive ζ-potential value of ca. 40 mV. Furthermore, the 
physical stability of emulsions was evaluated by monitoring 
changes in the droplet size and charge during storage under 
lightning conditions and at room temperature. Thus, primary 
emulsions did not show significant changes in average droplet 
size after 4 weeks. However, secondary emulsions showed a 
slight size increase from 249 nm to 274 nm due to flocculation 
phenomenon. Finally, tertiary emulsions presented a decrease 
from 416 nm to 388 nm, due to rearrangements of ε-poly-L-
lysine chains into a denser packing at the interface. Primary 
emulsions exhibited an important decrease in ζ-potential from 
45.8 mV to 15.9 mV after 4 weeks, indicating differences in the 
net charge of the protein-coated droplets. On the other hand, 
secondary and tertiary emulsions remained stable during the 
storage, suggesting an improvement in the stability due to an 
additional interfacial layer. Morphological studies using 
transmission electron microscopy confirmed that emulsions 
showed different microstructures depending on the layer 
composition. For instance, primary emulsions of lactoferrin-
coated oil droplets revealed a well-defined spherical shape 
surrounded by a lactoferrin layer. The lactoferrin/alginate-coated 
droplets in secondary emulsions were also spherical with a light 
inner region and a slightly dark outer region conforming the two-
layer coating. The oil droplets coated by three layers instead, 
had a light core and a visible intense black coating that 
corresponds to the multilayer coating. Nevertheless, a significant 
decrease in RSV loading was observed for RSV-loaded oil 
(control), 53 % after 4 weeks, and it was attributed to the 
chemical instability of RSV under environmental conditions. 
 
 
Figure 8. Images obtained by TEM of A) primary emulsions, B) secondary 
emulsions, and C) tertiary emulsions (magnification: 10000×). Scale bars = 
100 nm. Adapted with permission from ref. 37. Copyright 2017, Elsevier. 
 
In a recent work, Matos and co-workers reported the 
preparation of concentrated W/O/W double emulsions to entrap 
RSV using a conventional two-step mechanical emulsification 
process.[38] The compositions of these double emulsions were 
the same to the previously reported by the same authors.[36] 
Regarding the physicochemical characterization, the 
formulations presented a bimodal and highly polydisperse 
droplet size distribution with a mean peak in the 10–30 µm range. 
However, the samples presented good physical stability since 
were monitored for 9 days at 30 °C and no changes were 
noticed. The EE of RSV was 77.5 %. Finally, the double 
emulsions showed shear-thinning behavior and dominant elastic 
character. 
These results suggest that emulsions are good carriers for 
RSV delivery due to the good stability of some formulations. In 
this sense, some single colloidal systems remained stable 
practically for one year (348 days), whereas in another cases, 
additional interfacial layers (as in secondary and tertiary 
emulsions) improved the stability of the systems. The observed 





2.3.1 Lipidic particles 
 
Lipidic particles have a solid hydrophobic core stabilized by a 
hydrophilic layer of polymers or surfactant molecules. Scalia and 
co-workers developed lipidic microparticles coated with chitosan 
medium MW, with the aim to enhance in vivo human skin 
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Tristearin as lipidic material and hydrogenated 
phosphatidylcholine (1.4 %, w/v) as surfactant. In this example, 
6.5–8 % w/w of RSV was dispersed in the molten lipid phase. 
Chitosan is a natural cationic polysaccharide and was selected 
as coating material due to its biocompatibility and absorption 
properties, and was used in acetic acid (1 % w/v; pH 4.2). Lipidic 
microparticles (LMs) were prepared using melt emulsification 
and sonication method. The results showed that obtained LMs 
were spherical in shape a displayed a smooth surface (Figure 9). 
On the other hand, mean diameters obtained for uncoated and 
coated LMs were similar (6 µm) while PDI was minor for coated 
microparticles (PDI: 0.4 vs. 0.14) indicating homogeneous 
distribution on particles sizes. RSV EE was 67 % for uncoated 
and 62 % for coated LMs. In addition, ζ-potential values 
obtained for uncoated LMs was –18 ± 5 mV, while for coated 
microparticles was 64 ± 4 mV due to coated chitosan cationic 
nature. 
 Later, Trotta and co-workers developed LMs for RSV 
delivery to the brain via nose. The LMs were prepared with 
stearic acid and phosphatidylcholine coated with chitosan 
(8.75 % w/v, pH 4.2) using the same methodology  
aforementioned. These particles were irregular in shape, with a 
mean diameter of 85 µm, and presented an encapsulation 
efficiency of 81 %. The ζ-potential measurements indicated a 
high positive value of 45 ± 3 mV which did not show variation 
after six months of storage at 4 °C, demonstrating a good 
stability.[40] 
 
Figure 9. SEM micrograph of chitosan-coated lipidic microparticles loaded 
with RSV and produced by the optimized procedure. Adapted with permission 
from ref. 39. Copyright 2015, Elsevier. 
 
Similarly, Wu and co-workers prepared RSV-loaded chitosan 
nanoparticles via anionic cross-linking for chemotherapy.[41] The 
nanoparticles were made of positively charged chitosan and 
Poloxamer 188. The negatively charged tripolyphosphate was 
chosen as the cross-linking agent, to improve the stability, 
solubility and tumors targeting of the natural anti-cancer RSV. 
RSV-loaded formulations were prepared with 5 g/L. The 
obtained particles showed spherical shape with a mean 
diameter of 217 ± 10 nm and a narrow PDI of 0.26 ± 0.03. The ζ-
potential of RSV-nanoparticles was 59 ± 6 mV, suggesting a 
high stability of the system. Nevertheless, the EE of RSV was 
only 11.7 ± 0.4 %. 
An evaluation of scavenging capacity and antioxidant 
damage effect of lipidic nanostructured carriers loaded with RSV 
was carried out by Jin and co-workers.[42] The lipidic nanocarriers 
for this study were composed by glyceryl behenate, olive oil, 
Kolliphor EL, TPGS and water. In this case, 0.5 % w/w of RSV 
powder was dispersed in the lipidic mixture. RSV-nanocapsules 
were prepared by hot melting followed by high pressure 
homogenization. The particle size was 140 ± 2 nm, with a PDI of 
0.22 and a ζ-potential of –11.2 ± 0.4 mV. 
The effect of a chitosan derivative was also evaluated on 
the surface modification of solid lipidic nanoparticles loaded with 
RSV, using TMC-g-PA.[ 43 ] TMC-g-PA is a grafted cationic 
polymer formed by N-trimethyl chitosan (TMC) modified with 
palmitic acid. This conjugate forms hydrophobic core-hydrophilic 
shell micellar structures in aqueous media. The nanoparticles 
were composed of Precirol® ATO 5, palmitic acid, Gelucire® 
50/13, Tween 80 and 5.45 % w/w of RSV and were prepared 
using hot-melt emulsification and ultrasonication. In addition, the 
nanoparticles surface modification was performed by simple 
mixing of the components. Modified RSV-nanoparticles showed 
larger size than unmodified ones with a mean particle size of 
258 ± 19 nm vs. 100 ± 14 nm and similar PDI values 0.27 ± 0.05 
vs. 0.32 ± 0.03, respectively. Furthermore, positive ζ-potential 
value was found for modified RSV-nanoparticles (21 ± 1 mV) in 
comparison with unmodified nanoparticles (–19.1 ± 0.4 mV) 
confirming the surface modification. DSC and FT-IR studies 
confirmed the encapsulation of RSV, which occurred with an EE 
of 95 ± 2 %. Stability studies indicated no significant differences 
in particle size, ζ-potential and EE for modified and unmodified 
formulations stored at 25 °C and 4 °C for three months. 
Singh and co-workers also designed solid lipidic 
nanoparticles loaded with RSV for the treatment of liver 
cirrhosis.[44] The nanoparticles were prepared by solvent injection 
using glyceryl behenate, Gelucire® 50/13 and Tween 80. In this 
case, 20 g/L of RSV was added in the organic phase. The 
optimized formulations consisted of particles with nearly 
spherical shape and a mean diameter of 191 ± 10 nm, PDI 0.16 
± 0.05, and ζ-potential of (–14 ± 4) mV. In this system, RSV EE 
was established in 74 ± 4 %. DSC and X-ray diffractometry 
(XRD) studies confirmed the encapsulation of RSV owing to the 
effect of nanoparticles on the reduction of crystallinity and 
enhancement of stability.  
The preparation of a different kind of nanoparticles 
functionalized with apolipoprotein E (ApoE) for the delivery of 
RSV into the brain was reported by Neves and co-workers.[45] 
The nanoparticles were prepared using hot-melt emulsification 
followed by high shear homogenization and sonication. The 
formulation contained cetylpalmitate, RSV (5 g/L) and Tween 80. 
The binding of ApoE to nanoparticles surface was carried out by 
spontaneous interaction between the previously biotinylated 
ApoE and covalently attached avidin on the particle surface. The 
obtained ApoE-nanoparticles were almost spherical and uniform 
in shape with a mean diameter of about 218 ± 6 nm, with a PDI 
value of 0.08 ± 0.030 and a ζ-potential of –13 ± 2 mV. It is worth 
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Chang and co-workers described another RSV delivery 
system based on grape peel extract (GPE) and dripping pill (DP) 
for oral administration.[46] The solid dispersion was formed mixing 
GPE, Capryol™ 90, Poloxamer 188, Cremophor® EL and PEG 
6000. The GPE-DP formulation was prepared using the hot-melt 
method affording approximately spherical particles with a mean 
size of 3.53 ± 0.08 mm, with a RSV content of 1.23 % w/w. 
Furthermore, GPE-DP formulation was found to retain 92 % of 
RSV at 40 °C and 75 % relative humidity during 6 months. 
 
2.3.2 Proteic particles 
 
Koga and co-workers evaluated the stability of RSV 
encapsulated in microparticles made of proteins using the spray 
drying method.[47] A dairy protein such as sodium caseinate and 
4.8 % w/w of RSV composed the best formulation. The particles, 
with estimated sizes between 1 and 20 µm, were no spherical 
and showed wrinkled surfaces (Figure 10). Besides, RSV 
microencapsulation efficiency was 68 %. 
 
 
Figure 10. SEM images of RSV microcapsules (microparticles). Adapted with 
permission from ref. 477. Copyright 2016, Elsevier. 
 
RSV was also encapsulated within soy protein isolate (SPI) 
nanoparticles using a simple rotary evaporation technique by 
Pujara and co-workers.[ 48 ] A SPI-RSV complex formed the 
formulation, for which a RSV solution in ethanol (1 g/L) was 
dropped onto the SPI dispersion. Furthermore, RSV-
encapsulated SPI complexes were evaluated for size, ζ-potential, 
solubility, in vitro drug release and anti-inflammatory activity. 
The nanocomplexes showed a spherical morphology, with a 
particle size of 525 ± 33 nm, a PDI value of 0.56 ± 0.03 and a 
highly negative ζ-potential of (–35.8 ± 0.6) mV. The 
encapsulation of RSV was confirmed by wide angle XRD and 
DSC. In both cases, no obvious peaks originating from pure 
RSV could be observed indicating its amorphous state within the 
SPI complexes. 
Another strategy was reported by Liu and co-workers, who 
developed a colloidal delivery system based on protein-
polyphenol conjugates, protected with a natural surfactant, for 
RSV and CUR delivery.[49 ] The nanoparticles were fabricated 
using the antisolvent precipitation method, and a corn oil 
emulsion in the final step to improve the bioaccesibility. The 
hydrophobic core was composed by zein-epigallocatechin 
gallate conjugates, while the shell was made of rhamnolipid 
(biosurfactant). A corn oil emulsion was used to improve the 
bioaccesibility. The results revealed that CUR and RSV could be 
successfully co-encapsulated in the core-shell nanoparticles. 
The obtained particles were spherical with a mean diameter of 
121 ± 1 nm, a low PDI value of 0.19 ± 0.01 and a ζ-potential 
value of –36.5 ± 0.1 mV due to the presence of a carboxylic acid 
group in the molecular structure of the rhamnolipids. Besides, 
the encapsulation of RSV in an amorphous form was confirmed 
by spectroscopic analyses. Interestingly, when both polyphenols 
were simultaneously encapsulated, the EE of RSV was 
increased from 78 % to 85 %. The nanoparticles were relatively 
stable to aggregation from pH 4 to 9 and at low salt 
concentration (< 50 mM). 
 In another work, Guo and co-workers developed 
hyalurosomes via self assembly of a mixture of oligo-hyaluronic 
acid-curcumin polymer and soybean phospholipids, to improve 
the performance of CUR and RSV. The particles were spherical 
in shape with a mean diameter of 135 ± 5 nm and a negative ζ-
potential value of –29 ± 1 mV at pH 7.4 phosphate buffer 
solution conditions. The encapsulation efficiency of both 
polyphenols was 58.8 %, and the proposed delivery system was 
stable during 5 months at room temperature.[50] 
 An interesting proposal was developed by Dai and co-
workers, whom prepared lignin nanoparticles loaded with RSV 
and magnetic nanoparticles (Fe3O4). This green carrier had a 
diameter of ∼160 nm, relatively uniform size distribution and a 




Lipid-core nanocapsules are a specific type of nanocapsules 
composed of an oily core surrounded by a polymeric shell 
stabilized by surfactant in aqueous medium. Friedrich and co-
workers investigated the behavior of lipid-core nanocapsules 
loaded with RSV and CUR in human skin penetration.[52] The oily 
core of nanocapsules was composed of Span 60 and grape 
seed oil, whereas the polymeric shell was formed by poly(ε-
caprolactone). Tween 80 was used as non-ionic surfactant to 
stabilize the nanocapsules in aqueous medium, which were 
prepared by the interfacial polymer deposition method. For the 
polyphenol-loaded formulations, a concentration of 3.5 % w/w 
was added. RSV-CUR-nanocapsules were characterized by a 
spherical shape of 201 nm in diameter, a PDI of 0.09 and a 
slightly negative ζ-potential value of –8 ± 1 mV resulting from the 
coating by Tween 80. The pH of suspension was 6.5 ± 0.1. The 
EE was 99.80 ± 0.02 % and 99.94 ± 0.04 % for RSV and CUR, 
respectively. No differences were observed in the 
physicochemical properties in comparison to single loaded 
nanocapsules. 
 
2.3.4 Mesoporous silica nanoparticles 
 
Summerlin and co-workers encapsulated RSV into mesoporous 
silica nanospheres (MCM-48) and tested its efficacy in anti-
inflammatory and anti-carcinogenic assays.[ 53 ] Nanoparticles 
were synthesized based on the Stöber method in presence of a 
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silica source and tri-block copolymer F127 (Pluronic F127) acted 
as particle dispersion agent, whereas cetyltrimethylammonium 
bromide and ethanol was the structure-directing mixture. 20 % 
w/w of RSV was added to the prepared MCM-48. 
Physicochemical characterization of nanoparticles showed cubic 
pores in an ordered array, a size of 283 nm with a PDI of 0.25 
and a ζ-potential of –22.2 mV. RSV encapsulation was verified 
by XRD due to reduction of nanoparticles surface area after 
encapsulation and amorphous nature of RVS within nanopores 
of MCM-48 (RSV free form was crystalline). 
Juère and co-workers reported another example of RSV 
encapsulated in mesoporous silica nanoparticles. The 
formulation was also made of MCM-48 silica type to encapsulate 
20 % w/w of RSV.[54] The nanoparticles had a diameter of 90 nm 
with a pore size of 3.5 nm and were mostly spherical. The 
encapsulation of RSV was confirmed via wide-angle powder 
XRD since no reflections associated to the crystallized state of 
the RSV was detected. In addition, RSV stability from a 10-
month-old formulation was studied by UV-Vis spectroscopy and 
powder XRD. The results confirmed RSV stability against 




Singh and co-workers prepared stable RSV nanocrystals with 
stabilizers to improve its oral bioavailability.[55] The nanocrystals 
were fabricated using probe sonication. The composition of the 
optimized formulation was TPGS, Lecithin and Pluronic F127 
(2:1:0.5) % w/v. RSV-nanocrystals showed rod like 
morphologies with a particle size of (110 ± 13) nm and a PDI of 
0.18 ± 0.03 (Figure 11). The ζ-potential obtained for this 
formulation was –33 ± 4 mV. Moreover, the EE of RSV was 94 ± 
2 %. In addition, the nanocrystals were stable over a period of 3 
months without detriment of their physicochemical properties. 
 With the aim to improve RSV topical delivery, Sinico and 
co-workers developed polyphenol nanocrystals with the wet 
media milling method. In this work, the authors used Poloxamer 
188 and Tween 80 as stabilizers. The resultant nanoparticles 
were spherical and smooth in shape, their size ranged between 
0.2-0.3 µm with a homogeneous distribution (PDI, 0.16-0.25). All 
the formulations presented negative ζ-potential values (-30/-34 
mV) and their stability depended on the stabilizer used. Thus, 
Poloxamer 188-stabilized nanosuspension increased ∼100 % 
their size in 60 days at 25 °C while Tween 80 ones retained a 
similar size and PDI values at the same conditions.[56] 
 
 
Figure 11. SEM photomicrograph showing the surface morphology of 
lyophilized trans-RSV nanocrystals. Reproduced with permission from ref. 555. 
Copyright 2017, Springer. 
 
2.4 Combining delivery systems 
 
The combination of several approaches to obtained new carriers 
constitutes also an interesting alternative to previously 
mentioned systems are. For instance, Negi and co-workers 
designed a topical RSV delivery system combining niosomes 
and hydrogels for treatment of pain disorders.[57] The hydrogel 
matrix was prepared with Carbopol® 934, due to its hydrophilic 
and bio-adhesive properties, whereas the niosomes were 
prepared by TFH using a mixture of Span 80 and cholesterol. 
The niosomal formulation containing Span 80:cholesterol-2:1 
mass ratio and 0.83 % w/w of RSV, was found to be the most 
stable one, showing the lowest sedimentation volume and 
smallest average particle size (307.4 ± 0.3 nm). RSV EE in 
these niosomes was estimated in 67 ± 1 %. The resulting 
niosomal hydrogel showed a pseudoplastic behavior (yield value 
= 63.13 Pa) and a pH of 7.1, which is similar to the pH of the 
skin. In addition, the bioadhesive gel was easy to spread and 
could be extruded from tube. 
The co-encapsulation of RSV-CD inclusion complex in the 
lipophilic and hydrophilic compartments of liposomes was 
recently developed as a novel RSV carrier (Figure 12).[ 58 ] 
Liposomes were composed by 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and cholesterol at a concentration of 2 
mg/mL. In this case, the preparation method was the TFH 
combined with extrusion. The RSV-CD inclusion complex was 
formed with 2-hydroxypropyl-γ-cyclodextrin (2-HP-γ-CD) at a 
molar ratio of 2:1. The particle size, PDI and ζ-potential of the 
final formulation were 131 ± 1 nm, 0.089 ± 0.005 and –2.6 ± 0.5 
mV, respectively. Moreover, the final formulation was stable at 
least for 7 days at 4 °C. Importantly, the RSV EE was enhanced 
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Figure 12. Schematic representation of the RSV delivery system based on a 
dual nanoencapsulation approach using liposomes and cyclodextrin inclusion 
complex. Adapted with permission from ref. 58. Copyright 2016, Elsevier. 
 
RSV-CD also was encapsulated in a phospholipid-
stabilized nanoemulsions prepared by ultrasound-assisted 
emulsification.[59] RSV-CD-nanoemulsions were prepared mixing 
appropriate amounts of water/oil, lecithin and Tween 80. The 
resulted formulation showed spherical globules with an average 
size of 24 ± 6 nm, a narrow PDI of 0.30 ± 0.03 and a high 
positive ζ-potential (33 ± 4 mV). Moreover, the droplets were 
stable up to 4 months with no significant changes observed on 
particle size and UV-visible absorption of the system. The EE of 
RSV-CD in nanoemulsions was of 99.95 %. Various 
physicochemical parameters of nanoemulsions were obtained at 
37 °C, such as pH, refractive index, surface tension and 
viscosity. The values obtained were 6.66 ± 0.05, 1.356 ± 0.001 
ND, 27.0 ± 0.5 mN/m and 2.3 ± 0.7 Ns/m2, respectively. These 
results suggested that the formulation could be used as delivery 
vehicle since it was slightly acidic, homogeneous and stable, 
with good spreading and mixing of components and fully 
dilutable. 
Another approach was developed by Hao and co-workers, 
who reported the in situ fabrication of a gel, using deacetylated 
gellan gum (DGG), loaded with RSV nanosuspensions for 
intranasal drug delivery.[60] DGG is an anionic polysaccharide 
that can form transparent gels on exposure to certain 
concentrations of cations found in the nasal mucosa mucus. 
RSV nanosuspensions were prepared according to the solvent 
precipitation method. Lyophilized nanosuspensions were 
introduced in DGG solutions and mixed, to obtain the final 
formulation. The best formulation contained 0.6 % w/v of gellan 
gum due to favorable gelling ability and desired viscosity. 
Particle analysis showed spherical shape with a mean diameter 
of 241 nm and a PDI of 0.23. The ζ-potential was -9 mV and the 
colloidal suspension was stable during 30 days storage at room 
temperature. Furthermore, the rheological studies indicated that 
this formulation showed shear thinning and thixotropic properties. 
In addition, the rheological behavior obtained for the in situ gel 
revealed adequate mechanical properties for intranasal 
administration, since high values of adhesiveness were obtained, 
indicating a prolonged residence time on the application site and 
low values of cohesiveness, demonstrating good spreading and 
covering of the formulation over the mucosal tissue. 
El-Far and co-workers reported an alternative system.  The 
authors fabricated a multicompartmental nanovehicle based on 
casein micelles and phytosomes for delivering antineoplasic 
drugs, monascus yellow pigments and RSV.[ 61 ] A complex 
between phosphatidylcholine and RSV composed the 
phytosome. Accurate quantities of pigments and casein were 
used to prepare the loaded micelles, whose dispersion was then 
used to hydrate the film of phytosome. Physicochemical 
characteristics of dual drug-loaded casein micelles revealed 
smooth spherical morphology, a particle size of 225 ± 9 nm with 
a PDI of 0.21 ± 0.02 and a ζ-potential value of –54 ± 5 mV. 
Moreover, RSV was encapsulated with 82 % efficiency. The 
disappearance of the melting endothermic peak of pure RSV at 
around 265 °C in the DSC thermogram confirmed the formation 
of phytosomal complex. In addition, the particle size was not 
increased from initial measurements after 3 months of storage at 
4 °C, confirming the physical stability of the formulation. 
 




There are several systems where the solubility of RSV was 
increased due its incorporation in different carriers. The most 
important increment in the solubility of RSV was obtained in the 
GPE-DP formulation (solid dispersion of the mixture of GPE, 
Capryol™ 90, Poloxamer 188, Cremophor® EL and PEG 6000).  
[
466
] In this system the RSV solubility was ca. 14 times higher 
than in GPE alone (i.e. 63.1 ± 1.0 µg/mL vs. 903.9 ± 7.4 µg/mL). 
A similar enhancement was observed in RSV nanocrystals 
stabilized with Tween 80 where the polyphenol solubility 
increased from 65 ± 3 µg/mL (for bulk RSV) to 902 ± 2 µg/mL.[56] 
In contrast, RSV-SPI complex nanoparticles enhanced 2-fold the 
solubility of RSV in relation with unencapsulated RSV.[48] 
Similarly, MCM-48 also enhanced, approximately 2 times, the 
RSV solubility when it was encapsulated.[53] 
 
3.1.1 In vitro release studies 
 
Several in vitro release studies of RSV were carried out using 
different delivery systems and experimental conditions. In some 
examples, the systems showed sustained release. Thus, RSV 
release from succinyl chitosan-stabilized liposomes was 15 % 
after 2 h at pH 1.2, and an almost complete release of RSV after 
8 h at pH 7.0 and at 37 °C was observed. The observed 
difference could be due to the high solubility of the 
polysaccharide at neutral pH.[21] 
In vitro RSV release studies from chitosan nanoparticles 
were also performed at body temperature (37 °C) and pH values 
of 7.4 and 6.5, to mimic both physiological and tumor tissue 
conditions, respectively. The release from nanoparticles 
exhibited a biphasic pattern characterized by a fast initial burst 
effect during the first 2 h, followed by a slow and sustained 
release. The accumulated RSV release was 40 % at pH 7.4 and 
50 % at pH 6.5 over a period of 12 h (Figure 13). These results 
suggest that the weak acidic condition of tumor tissues is 
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Figure 13. In vitro RSV release profiles of RSV-chitosan particles. Data are 
means ± S.D., n=3. Accumulated RSV release content in pH 6.5 solution is 
higher than that of pH 7.4. Adapted with permission from ref. 41. Copyright 
2017, Elsevier. 
 
Similar results were obtained when RSV in vitro release 
studies were performed at 34 °C from lipidic nanoemulsions. In 
these studies ca. 60 % of RSV was released after 6 h at pH 6 
through a diffusion-controlled mechanism (Figure 14).[25] 
Additionally, the in vitro release study of RSV from RSV-
CD complex encapsulated in phospholipid nanoemulsions was 
carried out in phosphate buffer saline at pH 7.4 and 37 °C.[59] 
The cumulative releases (%) of RSV and RSV-CD from 
nanoemulsions were similar (ca. 55 %) after 15 h, also both 
release profiles showed fast and then sustained release. The 
initial fast release could be due to RSV present at the interface 
of nanoemulsions, which came out into aqueous medium rapidly. 
In contrast, the slow release could be attributed to the 
hydrophobic interactions between the oily core of 
nanoemulsions and RSV, or hydrogen bonding interaction 
between hydroxyl group of CD and surfactant molecules.  
In all these cases, the RSV sustained release was higher 
and faster from surface modified liposomes. Then, chitosan 
nanoparticles and RSV-CD complex in nanoemulsions showed a 




Figure 14. In vitro release of RSV and CUR from the mucoadhesive 
nanoemulsion coated with HA in phosphate buffered saline pH 6 containing 
2 % Tween 80. Adapted with permission from ref. 25. Copyright 2016, Informa 
Pharmaceutical Science. 
 
It is well known that delivery systems could reduce the 
release of diverse encapsulated compounds because of many 
causes. For example, it could be due to the lipophilicity of the 
entrapped drug. RSV release from niosomes (Span 60 and cetyl 
alcohol) in simulated gastrointestinal conditions showed a 30 % 
and 9 % of RSV within 2 h at pH 1.2 from free solution and 
niosomes, respectively. Later, at pH 7.4, ca. 96% of RSV was 
released from its free form within 7 h, while the 




Figure. 15. In vitro release profile of free resveratrol and resveratrol 
encapsulated in niosomes (R-niosomes). The first 2 h of dialysis was carried 
out in a solution maintained at pH 1.2 using 0.1 N HCl and it was continued in 
phosphate buffer solution at pH 7.4 for 10 h, to simulate the gastric and the 
intestinal conditions, respectively. Adapted with permission from ref. 19. 
Copyright 2018, Elsevier. 
 
In a similar way, RSV release from nanoemulsions 
(soybean oil, soy lecithin, Labrasol and water) after 24 h was 
significantly slower than from plain solution (60 % vs. 100 %, 
respectively).[24] Similar results were obtained from 
nanoemulsions coated with PFPE. The emulsion showed a 
controlled release of RSV in phosphate buffer saline at pH 7.4 
and 37 °C thus 57 % of RSV was released from this formulation, 
whereas a maximum of 70 % was obtained for free RSV solution 
after 285 h.[27] The same tendency was observed from SMEDDS 
(composed of Labrafil, Labrasol and Cremophor RH 40 as oil 
phase). The RSV in vitro release was 27 % from SMEDDS, and 
80 % was rapidly released from the free RSV suspension within 
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Figure 16 Percentage of RSV released as a function of time from free drug or 
self-microemulsifying drug delivery system (SMEDDS) (n=3, mean ± S.D). • 
Free RSV, ! SMEDDS containing UGT inhibitory excipients, ! control 
SMEDDS (without UGT inhibitory excipients). Adapted with permission from 
ref. 30. Copyright 2018, Elsevier. 
 
A nanovehicle based on casein micelles and phytosomes 
exhibited a biphasic release profile of RSV characterized by 
initial burst release, followed by a prolonged release phase. 
After 24 h, 72 % of RSV was released from phytosomal-micelles, 
whereas free RSV was completely released from its solution 
within 2 h at pH 7.4 and 37 °C.[61] In the aforementioned 
examples, the reduction of RSV release was achieved more 
effectively using nanoemulsions, specifically with PFPE coated 
ones in comparison with niosomes, microemulsions and 
phytosomal-micelles. 
A reduction of RSV release occasionally is caused by the 
delivery system surface modification. For example, the in vitro 
release profile of RSV from PEG-modified liposomes was 
constant and slower than from conventional liposomes (20 % vs. 
45 % after 8 h), achieving the same value after 24 h (ca. 
70 %).[22] Hence, the proposed formulation could modulate the 
release in a time-dependent manner, and PEG-surfactants 
played an important role in controlling the release rate.  
Similarly, lipidic microparticles coated with chitosan showed a ca. 
30 % of RSV release in 6 h whereas 50 % was released from a 




Figure 17. Franz diffusion cell release profiles of free RSV (filled triangles), 
uncoated RSV-loaded lipidic microparticles (filled squares) or chitosan-coated 
RSV-loaded lipidic microparticles (filled circles) from their cream formulations. 
Values are means ± S.D. (n=6). Adapted with permission from ref. 39. 
Copyright 2015, Elsevier. 
 
In gastrointestinal simulated conditions, RSV solid lipidic 
nanoparticles, showed an initial burst release at pH 1.2, and 
sustained release pattern at pH 6.8 after 24 h, 74 ± 4 % and 68 
± 4 %, respectively. When modified lipidic nanoparticles with 
TMC-g-palmitic acid were used, 43 ± 2 % of RSV was released 
in a sustained manner at pH 6.8, whereas it was less than 25 % 
at pH 6.8.[43] 
Solid lipidic nanoparticles ApoE functionalized reduced ca. 
1.5 times the RSV release and the initial burst effect was 
avoided in comparison with non-functionalized ones after 28 h, 
in blood stream simulated conditions at 37 °C.[45] 
In the case of niosomal hydrogel system, the slower RSV 
release in comparison with a suspension could be attributed to 
higher diffusion limitations in the hydrogel matrix. In this sense, 
90% of RSV was released over 6 h, being only slightly slower 
from the niosomal hydrogel compared to a suspension 
formulation. Among different mathematical models, the 
Korsmeyer-Peppas kinetic model provided the best fitting for 
both niosomal and suspension formulations.[57]  
These results indicate that the surface modification was an 
appropriate strategy to reduce the RSV release, specifically in 
liposomes. Indeed, a reduction of 2.2 times was observed, while 
in the other cases this decreasing was ca. 1.5 times. 
In sharp contrast the release of RSV could also be 
enhanced and in many cases, the enhancement is attributed to 
the increment in its aqueous solubility. In this sense, in vitro 
release studies from SNEDDS (made of lignin sulfonate/Tween 
80/PEG-400 and olive oil) were performed at 37 °C and pH 
values of 1.2 and 6.8. Under both simulated conditions, RSV 
was released faster from lignin SNEDDS (ca. 2 times higher 
than from pure RSV solution) (Figure 18). Thus, the proposed 
formulation contributed to improve the dispersion and dissolution 
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Figure 18. Cumulative trans-RSV release of self-nanoemulsifying drug 
delivery system (SNEDDS) and pure RSV from dialysis bag in A) pH 1.2 and 
B) pH 6.8. Adapted with permission from ref. 33. Copyright 2018, John Wiley & 
Sons. 
 
Regarding lipidic nanoparticles, some RSV in vitro release 
studies showed an enhanced release at the same time, in 
comparison with a control suspension. For example, 80 ± 4 % of 
RSV was released from modified nanoparticles while 37 ± 5 % 
was released from RSV control suspension at pH 7.4 and 37 °C 
after 24 h.[44] 
In comparison, in vitro release experiments were carried 
out at 37 °C, at pH 1.2 and 6.8. Final accumulated release of 
RSV from GPE at pH 1.2 was only 23 ± 1 %, while that from 
GPE-DP was 67.8 ± 0.4 %. Moreover, at pH 6.8 the values were 
14.9 ± 0.5 % and 64.5 ± 0.7 % for GPE and GPE-DP, 
respectively. These results confirmed the significant increase in 
RSV solubility due to GPE-DP formulation.[46] 
In the same conditions above mentioned, RSV was 
released from the SPI nanoparticles faster compared to pure 
RSV solution in both conditions. After 2 h at pH 1.2, 60 % of 
RSV was released from the proposed formulation and only 16 % 
from pure RSV solution. After 24 h in intestinal conditions, ca. 
50 % of RSV was release from the control solution and ca. 90 % 
from the nanocomplexes (Figure 19). This faster release can be 







Figure 19. In vitro release of pure RSV and RSV encapsulated in soy protein 
isolate nanocomplex (SPI-RSV). Mean ± S.D. (n=3). Adapted with permission 
from ref. 48. Copyright 2017, Elsevier. 
 
Another study of in vitro drug release was performed at pH 
7.4 and 32 °C from lipid-core nanocapsules, loaded with RSV, or 
with RSV-CUR co-encapsulated. After 6 h, no considerable 
differences were observed in RSV release, i.e. ca. 38 % from 
RSV-nanocapsules and ca. 43 % from RSV-CUR-nanocapsules. 
However, after 24 h, ca. 73 % of RSV was release from RSV-
CUR-nanocapsules and ca. 58 % from RSV-nanocapsules 
(Figure 20). Such enhancement of the release kinetics 
suggested a promoted release due to co-encapsulation.[52] 
 
 
Figure 20. In vitro release profiles of RSV and CUR from lipid-core 
nanocapsules (LNC) (n=3) at 32 °C. Release from RSV-CUR-LNC is depicted 
with circles (• RSV; " CUR), whereas ! and ! depict release curves for 
polyphenols from RSV-LNC and CUR-LNC, respectively. S.D., which were 
always below 1.06%, are not shown for CUR curves to maintain a clear data 
presentation. Adapted with permission from ref. 52. Copyright 2015, Elsevier. 
 
Studies of RSV release from RSV-CD inclusion complex-
liposomes were carried out at pH 7.4 and 37 °C for 24h. The 
cumulative release of RSV was almost complete for dual 
encapsulated liposomes (94 %) compared to its free form (44 %), 
due to the increased RSV aqueous solubility because of CD 
inclusion complex.[58] 
In vitro dissolution studies carried out at pH 7.4 and 37 °C  
with RSV encapsulated in nanoparticles made of MCM-48 silica 
type showed a 26 % of RSV released from a pure solution, 
whereas 70 % was released from the proposed formulation (with 
MCM-48) as a consequence of enhanced solubility. The release 
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the zero-order kinetic model drove the drug dissolution 
(diffusional exponent of 0.944) [54]. In the same medium (pH 
7.4 and 37 °C) in vitro RSV release studies were also performed 
from nanocrystals. After 5 h, 95 % of RSV was released from the 
formulation whereas only 40 % was released from plain RSV, 
which could result from the RSV dissolution rate enhancement 
with nanocrystals.[55] 
In the case of silica nanospheres of MCM-48 studied by 
Summerlin and co-workers, the faster diffusion and release of 
RSV was due to the RSV amorphous state and the higher 
surface area within nanoparticles, since the in vitro release was 
much slower from RSV in dimethyl sulfoxide solution (31 %) 
than from MCM-48 (65 %) after 24 h (Figure 21).[53] 
 
 
Figure 21. A) Saturated aqueous solubility of pure RSV, MCM-48-RSV-
Physical mixture (PM) and MCM-48-RSV (n=3 ± S.D., P value was determined 
by one-way ANOVA, ****P<0.0001). B) In vitro release of pure RSV and RSV 
loaded in MCM-48 in phosphate buffer saline (PBS) (n=3 ± S.D.). Adapted 
with permission from ref. 53. Copyright 2016, Elsevier. 
 
In gels from DGG loaded with RSV nanosuspensions, RSV 
exhibited significantly faster profiles (100 % in 6 h) than coarse 
suspension in situ gels (50 % at the same time). The authors 
explained these results regarding the small diameter particle 
size of the nanosuspension resulting in a higher dissolution rate. 
To understand the RSV release mechanism, different 
mathematical models were fitted. The results established that 
RSV release from gel nanosuspensions was diffusion-controlled 
according to the Higuchi model, while the release from gel 
coarse suspension corresponded to Zero order kinetic model, 
indicating concentration-independent drug release.[60] 
The major enhancement in the RSV release was a 
consequence of its improved solubility due to the encapsulation. 
The SPI nanoparticles caused the higher increase being the 
RSV release almost 4 times higher compared to free from. GPE-
DP formulation also showed a good performance and in this 
case the enhancement was ca. 3 times. 
 
3.2 Penetration and permeation studies 
 
In general, the formulations proposed enhanced the penetration 
and permeation of RSV in comparison with a control solution. 
For instance, HA coated nanoemulsions confirmed the skin 
penetration of RSV through ex vivo sheep nasal mucosal and 
showed a RSV flux of 2.86 µg/cm2h.[25] 
In vitro permeation analysis measured in porcine skin at 
37 °C showed that only 21 % of RSV was penetrated from 
ethanol solution, whereas 82 % was released from RSV-




Figure 22. In vitro permeation results of trans-RSV ethanol solution and trans-
RSV loaded in an emulsion with 2-HP-β-CD (NanoSolve). Adapted with 
permission from ref. 26. Copyright 2016, Taylor & Francis. 
 
It is worth mentioning that a higher cumulative amount of 
RSV-SNEDDS (composed of sodium lignin sulfonate/Tween 
80/PEG-400 as mixed surfactants and olive oil) was transported, 
from the apical-to-basolateral direction through Caco-2 cells 
monolayers, than from pure RSV solution.[33] 
Similarly, the permeability of the encapsulated RSV in 
MCM-48 nanospheres across tight junctions of Caco-2 
monolayers was more than 5 times higher than for RSV 
suspension.[54] 
RSV permeation through dorsal skin of Wistar rats was 
found to be superior using a niosomal hydrogel (88 % vs. 63 % 
for the plan drug suspension). Moreover, the skin retention for 
the niosomal gel was found to be 4.76 ± 0.21 mg/cm2, which 
corresponded to almost five times the value observed with plain 
drug suspension. Dermatokinetic studies confirmed the high 
RSV permeability in dermis and epidermis and the increase of 
its biological half-life using niosomal hydrogel.[57] 
In some cases, the improvement of RSV penetration and 
permeation were performed by reducing the size of particles or 
using penetration enhancers. In this sense, ex vivo penetration 
and permeation studies of RSV loaded niosomes were carried 
out using skin of newborn pig due to its similarity to the human 
skin. The authors found that the formulations prepared with EIM 
were more effective into dermis and epidermis layers, reaching 
21 % RSV penetration with surfactant/fatty acid 1:1 ratio, 
whereas the formulations prepared with TFH-sonication only 
reached 11 % at the same weight ratio (Figure 23). This could 
be due to the smaller size obtained using EIM, independently of 
the type of fatty acid used. Besides, it was observed that % RSV 
penetration was not dependent of the RSV EE.[16] 
 In vitro penetration experiments were performed with a 
nanosuspension (nanocrystals) using porcine ear skin via tape 
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nanosuspension form, the drug was found up to the twentieth 
strip of the skin while from coarse suspension only penetrated 
until the tenth strip.[56] 
 
 
Figure 23. RSV penetration in epidermis and dermis (EDD): influence of 
formulation and niosomes preparation method. Niosomes made of Gelot 64 
and Oleic Acid. TFH-S, thin film hydration combined with sonication method. 
EIM = Ethanol injection method. Adapted with permission from ref. 16. 
Copyright 2015, Elsevier. 
 
Skin diffusion studies of soy phosphatidylcholine and OA 
(penetration enhancer) liposomes were also carried out on 
newborn pig skin. The results obtained were compared with 
conventional liposomes (without penetration enhancers). RSV 
accumulation in the whole skin increased 1.7 times with OrCG-
liposomes and 2 times for LauFCC-liposomes. In the epidermis, 
RSV accumulation increased 1.3 and 2.5 times for OrCG and 
LauFCC-liposomes, respectively (Figure 24). Confocal imaging 
of the skin showed that the ultrastructure of the epidermis 
untreated appeared compact and thin, whereas the skin treated 
with the liposomal formulation became swollen and more fluid 
with loose structures, but without disrupting the integrity of the 
skin. Besides, a significant degree of skin hydration was also 
observed, which enhances its permeability and produces faster 
cutaneous diffusion of the drug by the vesicles.[20] 
 
 
Figure 24. RSV deposition into pig skin layers (SC, stratum corneum; Ep, 
epidermis; D, dermis) and whole skin after 8 h non-occlusive treatment with 
RSV loaded in liposomes containing OrCG and LauFCC (penetration 
enhancers). Each value is the mean ± S.D. of six experimental determinations. 
Adapted with permission from ref. 20. Copyright 2015, Elsevier. 
 
In a similar way, nanoemulsions significantly increased 
intestinal permeation of RSV across rat jejunum. The RSV fluxes 
in the mucosal to serosal direction increased 6 times for semi-
solid NE (nanoemulsions of Gelucire® 44-14 and Labrasol) and 
8 times for liquid-NE (nanoemulsion from Miglyol® 812 and 
Tween 80), compared to the control ethanolic RSV solution. 
Such significant difference was attributed to the nature of the 
formulations and to the droplet size difference between both 
nanoemulsions.[29] 
Other permeation studies helped to understand the RSV 
metabolism when it is encapsulated. In the case of Labrasol-
nanoemulsions, RSV metabolism was studied determining the 
permeation and the transport from serosal to mucosal layer 
(transfer rate) of RSV in rat small intestine. The results showed 
a 3.57-fold increase in transfer rate with Labrasol-
nanoemulsions compared to free RSV. The molar ratio between 
permeated RSV-3-glucuronide (RSV-G, metabolite) and RSV 
using free RSV and Labrasol-nanoemulsions was 7 ± 2 and 1.3 
± 0.1 respectively, indicating an inhibition of RSV 
glucoronidation due to encapsulation in nanoemulsions.[24] 
Furthermore, using SMEDDS (composed of Labrafil, 
Labrasol and Cremophor RH 40) in comparison with free RSV, 
the transport of RSV across Caco-2 cell monolayers was 
significant increased, ca. 4 times, indicating an improvement in 
RSV oral bioavailability. Besides, results from everted sacs of 
rats guts showed that RSV glucoronidation was notably inhibited 
when SMEDDS was used, since the molar ratio between RSV-
G/RSV was 0.36 ± 0.10 against 7.25 ± 0.48 observed for free 
drug.[30] 
In other examples, coating material improved the 
permeation of RSV from the formulation. In vivo skin penetration 
studies were carried out in volar forearm of human volunteers 
free of dermatological disorders using the tape striping 
technique [62,63]. The results indicated that the fraction of RSV 
penetrated in the upper portion of the stratum corneum was ca. 
49 % for chitosan-coated microparticles and ca. 33 % for 
uncoated ones. The former formulation also showed a marked 
and statistically significant increase of the fraction of RSV 
penetrated compared to the control formulation (29 %) in the 
same skin layers.[39] 
From solid lipidic nanoparticles (containing cetylpalmitate 
and Tween 80) functionalized with ApoE, permeability showed a 
significant increase (ca. 2 times higher) in penetration through 
hCMEC/D3 cells monolayers compared to non-functionalized 
ones.[45] 
When co-encapsulation was employed using lipid-core 
nanocapsules for delivery of RSV and CUR, skin penetration 
experiments showed that in stratum corneum the amount of 
RSV was ca. 3 times higher when a drug solution was used 
instead of RSV-CUR-nanocapsules. However, in epidermis and 
dermis higher amounts of RSV were observed from RSV-CUR-
nanocapsules. The penetration behavior of RSV from RSV-
CUR-nanocapsules was attributed, with the aid of FT-IR, to the 
interaction of CUR with stratum corneum bilayers that facilitate 
RSV penetration in inner skin layers.[52] 
In summary, the best results in penetration and permeation 
were found with nanoemulsions, such as semi solids and liquids, 
due to their composition and size. In contrast, vesicles slightly 
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The bioavailability of RSV was studied after administration via 
oral, intranasal or intravenous using different pharmacokinetic 
studies. 
After oral administration, the bioavailability of RSV 
encapsulated in Labrasol-nanoemulsions was evaluated using 
male Winstar rats. When Labrasol-nanoemulsions were 
administered, it was found a peak concentration (Cmax) of RSV in 
rat plasma, ca. 13-fold higher than free RSV. Moreover, the area 
under concentration-time curve (AUC) of RSV with Labrasol-
nanoemulsions was ca. 6 times higher that with free RSV. The 
ratio between AUCRSV-G and AUCRSV indicated an inhibitory 
effect of resveratrol-3-glucuronide (RSV-G) production due to 
Labrasol presence, since the ratio treated with Labrasol-
nanoemulsions was 0.88, a value considerable lower than that 
obtained with free RSV (10.12).[24] 
A remarkable impact of the formulation on the RSV 
metabolization pathways was also observed. In fact, in the 
permeation of RSV from an ethanolic solution through the 
serosal compartment, two main metabolites were observed. In 
contrast, these compounds were not observed when SNEDDS 
formulations were used.[29] 
Pharmacokinetic studies revealed that the oral 
bioavailability of optimized RSV-SNEDDS increased ca. 3 times 
compared with unformulated RSV solution, which was attributed 
to the increase in RSV solubility and the small particle size of 
SNEDDS.[28] 
Additionally, the biodistributions of RSV in the mesenteric 
lymph were measured after oral administration. SMEDDS 
formulations (composed of Labrafil, Labrasol and Cremophor 
RH 40) significantly improved the distribution of RSV in the 
intestinal lymph nodes compared with free drug at all time-points. 
Finally, the results obtained from in vivo pharmacokinetic study 
showed a RSV absolute bioavailability of 76 % (free RSV group 
revealed merely 6.5 %). Besides, the AUCRSV-G decreased 
significantly by 73 % compared with free RSV.[30] 
Various pharmacokinetic parameters revealed directly the 
enhanced adsorption rate of RSV SNEDDS. The AUC of the 
proposed formulation resulted in a 72-fold increase in 
bioavailability and Cmax value rose considerably to 24 fold as 
compared to RSV suspended in water.[33] Similarly, in vivo 
studies revealed a 5-fold increase of the bioavailability of RSV 
encapsulated in solid lipidic nanoparticles compared to RSV 
suspension. Furthermore, pharmacodynamic experiments 
showed a significant decrease in the serum biomarker enzymes 
(serum glutamic oxaloacetic transminase, serum glutamate 
pyruvate transminase and alkaline phosphatase) after oral 
administration of the proposed formulation in comparison with 
the control and marketed formulations against paracetamol-
induced liver cirrhosis.[44] 
In the case of TMC-g-palmitic acid SLNs, 
pharmacokinetics assays were performed in mice after oral dose 
of the formulation. The results showed that in that condition RSV 
oral bioavailability increased ca. 4 fold in comparison with SLNs. 
The authors describe this improvement as a result of the 
mucoadhesive and absorption properties of the polymer, which 
protects RSV from acidic and enzymatic gastric conditions.[43] 
Results obtained from other studies indicate that when GPE-DP 
formulation was used instead of GPE formulation, the RSV 
absorption via oral was raised ca. 12 times.[46] 
In addition, in vitro digestion tests were carried out to study 
the digestive stability and bioaccessibility of trans-RSV 
simulating oral, gastric and intestinal phases. RSV digestive 
stability was 81 % and 47 % for sodium caseinate microparticles 
and unencapsulated RSV, respectively. Moreover, the RSV 
bioaccessibility after 3-phase in vitro digestion from sodium 
caseinate microcapsules was 2.56 fold higher than the control 
(59 % vs. 23 %, respectively).[47] Moreover, the bioaccesibility of 
RSV was improved significantly when core-shell nanoparticles 
were mixed with lipid droplets (forming nanoemulsions), (i.e. 
43 % in absence and 90 % in the presence of nanoemulsions).[49] 
Regarding other pharmacokinetic studies, AUC0-∝ and Cmax 
of RSV were increased by 3.5- and 2.2-fold, respectively, when 
nanocrystals was used instead of plain RSV. Furthermore, mean 
residence time was raised ca. 1.2 times for RSV-nanocrystals 
(Figure 25). Such upgrading on RSV bioavailability could be due 
to several factors, such as the improved dissolution and reduced 
thickness of diffusion layer due to the small size, the increased 
bioadhesion of particles to the intestinal epithelium and the 
direct uptake of particles across the intestinal barrier.[55] 
 
 
Figure 25. Plasma concentration time profiles of RSV after oral administration 
of plain trans-RSV and trans-RSV-nanocapsules (NCs) to SD rats at 20 mg/kg 
dose. Values are expressed as the mean ± S.D. (n=6). Adapted with 
permission from ref. 55. Copyright 2017, Springer. 
 
Otherwise, the RSV bioavailability was analyzed through 
nasal mucosa and the in vivo quantification in the brain of male 
Albino rats, showed ca. 7-fold increase in AUC0-7 h when the 
nanoemulsion formulation was used instead of RSV free 
solution.[25] A drastic increase was observed in RSV uptake in 
the cerebrospinal fluid of rats using lipidic particles coated with 
chitosan (8.75 % v/w) in comparison with uncoated particles and 
pure RSV. Indeed, the obtained RSV Cmax after 60 min of nasal 
administration was 12.2-fold higher than for uncoated particles 
while no detectable amounts was noticed from pure RSV.[40] 
The bioavailability of RSV was also performed using gel 
nanosuspensions administered via intranasal and intravenous 
routes. The results showed that the bioavailability in brain was 
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instead of intravenous. Moreover, the brain drug direct 
transport % demonstrated that approximately 78 % of RSV was 
absorbed into the brain directly from the nasal cavity, while RSV 
into the brain was not detected using intravenous route.[60] 
In general, RSV bioavailability is a property scarcely 
studied. However, nanoemulsions were the delivery system that 
showed the best performance, either after oral or nasal 
administration. 
 
3.4. Stability against photoisomerization 
 
The stability of trans-RSV was studied after light exposure. For 
example, the isomer degradation in the SNEDDS was evaluated 
inside and outside the dialysis bag. Interestingly, the results 
showed that SNEDDS greatly reduced the photochemical 
degradation of trans-RSV, whereas the amount released and 
degraded of RSV from free solution was 50-50, which may be 
due to the directly contact with light and oxygen.[33] 
After direct UV irradiation the antioxidant activity of free 
RSV significantly decreased, but RSV in nanoparticles coated 
with chitosan still kept high activity, demonstrating than they 
could protect RSV from light destruction and increased its 
bioavailability.[41] 
On the other hand, UV measurements performed using 
UVA light of 365 nm for 1 h showed a trans/cis RSV ratio of 0.65 
for microparticles of sodium caseinate and 0.49 for 
unencapsulated RSV.[47] Moreover, when the samples were 
exposed to UV-light for 1 h, the retention of RSV free solution 
was 65 %, while the retention of RSV trapped in nanoparticles 
was 90 %. This effect was attributed to the presence of the 
nanoparticles, which decreased the amount of UV-light reaching 
the RSV due to light scattering or absorption effects.[49] Dai and 
co-workers also studied the structural stability of encapsulated 
RSV in lignin nanoparticles after 1 h of direct sun light. They 
observed only a decreased of 2 % of trans to cis RSV.[51] 
RSV-CD complex encapsulated in phospholipid 
nanoemulsions also prevented the degradation of RSV after UV 
irradiation (365 nm) (i.e. degradation % of RSV in water/ethanol 
was 64, where it was 25 within CD-nanoemulsions) (Figure 26). 
Although these nanoemulsions did not prevent completely the 
RSV degradation, they slowed down its rate. The formulation 
offers two protective layers (i.e. CD and nanoemulsions), which 
shielded RSV from UV light.[59] 
 
 
Figure 26. Absorbance reduction intensity plots of RSV in different conditions 
after UV irradiation (365 nm). NEm (nanoemulsions) and IC (inclusion 
cyclodextrin complex). Adapted with permission from ref. 59. Copyright 2017, 
Elsevier. 
 
In summary, even though the instability of bioactive RSV 
after light exposure is an important issue to be studied in a 
proposed formulation, just a few papers have provided such 
results. From those, core-shell nanoparticles mixed with lipid 
droplets retained almost the complete trans-RSV after 1 h of UV-




Regarding vesicles, niosomes formed by Span 60 and cetyl 
alcohol presented very low or negligible toxicity against 
RAW264.7 macrophage cells (i.e. 92.5 % of cell viability at 40 
µM)[19]. Similarly, liposomes formed by soy phosphatidylcholine 
and OA indicated non-cytotoxicity using 3T3 fibroblasts.[20] 
A different liposomal formulation (PEG-modified 
liposomes), was incubated with human erythrocytes and no 
significant effect was observed, whereas free RSV ethanolic 
solution caused human red blood cells hemolysis under the 
same conditions.[22] Similar results were observed with the 
nanoemulsion coated with HA, that did not cause any tissue 
damage or epithelial and ciliotoxicity in the nasal mucosa.[25] 
Additionally, macrophage uptake and imaging studies 
showed that the nanoemulsions were fully internalized by the 
macrophage cell line, RAW 264.7 cells. Importantly, the 
nanoemulsions did not affect macrophage viability of 
lipopolysaccharide-stimulated macrophages at the highest dose 
and decreased the NO production indicating no oxidative 
processes in the cells.[27] 
In another study of the cytotoxicity of SMEDDS (composed 
of Labrafil, Labrasol and Cremophor RH 40 as oil phase), the 
results indicated no increase of toxicity towards Caco-2 cells 
compared with free RSV.[30] 
Concerning the cell/tissue integrity and viability of 
SNEDDS (sodium lignin sulfonate/Tween 80/PEG-400 and olive 
oil), the authors reported that the system exhibited relatively 
lower toxicity than a pure RSV solution.[33] 
In vitro cell viability studies of solid lipid nanoparticles 
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NIH/3T3 mouse embryonic fibroblast cells and none of the 
formulations showed any significant toxicity.[43] Moreover, in vitro 
toxicity studies of solid lipid nanoparticles functionalized with 
ApoE revealed no toxicity up to 50 µM over 4 h of incubation 
using hCMEC/D3 cells.[45] 
In contrast, cell viability studies of lipid-core nanocapsules 
using human dermal fibroblasts showed a significant alteration 
of the profile compared to the control cells (80 %).[52] 
Furthermore, cell viability test was performed with Caco-2 and 
RAW 264 cells, indicating no significant toxicity of pristine MCM-
48 nanospheres.[54] 
Finally, in vitro hemolysis test of the multicompartamental 
nanovehicle based on casein micelles and phytosomes showed 
low or negligible hemolytic activity (< 5 %) indicating a safely 
parenteral delivery of the nanocarrier.[61] 
In general, most of the mentioned delivery systems 
showed negligible toxicity against different types of cells and 
they were found to be safe RSV carriers. 
 
4. Potential applications 
 
4.1. Pharmaceutical perspective 
 
4.1.1. Antioxidant activity 
 
As it is crucial to verify that the vesicle system does not alter 
RSV performance, in vitro antioxidant activity of RSV 
encapsulated in different systems was performed using 2,2-
diphenyl-1-picrylhydrazyl (DPPH) radical assays. 
No significant difference in scavenging activity was 
observed between free and encapsulated RSV in niosomas 
(Span 60 and cetyl alcohol) at the same concentration, 
confirming the retention of RSV biological functionality after its 
encapsulation into the vesicles. Besides, assays in macrophage 
RAW264.7 cell lines showed that niosomes have higher 
intracellular reactive oxygen species scavenging activity than 
those of RSV in its free form. Regarding this intracellular 
scavenging activity, lipopolysaccharide-stimulated macrophages 
showed a considerably reduction of fluorescence degree when 
RSV niosomes where used instead of free RSV. Thus, 
nanoencapsulation enhanced the functional property of RSV, 
possibly due to its higher degree of cell internalization.[19] 
The results of in vitro antioxidant activity assays of RSV in 
liposomas showed that the liposomal formulation did not affect 
the antioxidant activity of the polyphenol (93 ± 1 %), regardless 
the presence of PEG-surfactants. In addition, the antioxidant 
activity of RSV was assessed ex vivo in human erythrocytes by 
cellular antioxidant activity test, which revealed a dose-
dependent scavenging effect of RSV PEG-modified liposomes 
on oxidative stress induced by peroxyl radical generator on 
human red blood cells, regardless the concentration.[22] 
In addition, the pH of lipidic nanoemulsions developed by Nasr 
ranged from 6.6 – 6.7 and the antioxidant assay demonstrated 
no statistical differences in the percentage of radical inhibition 
upon RSV encapsulation.[25] 
It is very interesting to note that the antioxidant activity of 
multilayer (lactoferrin/alginate and lactoferrin/alginate/ε-poly-L-
lysine) emulsions containing RSV, did not present significant 
changes during storage using DPPH radical scavenging activity 
assay for 4 weeks.[37]  
In a similar way, the antioxidant activity of RSV could be 
maintained and enhanced after encapsulation into chitosan 
coated nanoparticles since the DPPH scavenging capacity was 
increased 10-30 % for RSV-nanoparticles in comparison with 
free RSV, which was attributed to the own activity of chitosan.[41] 
Besides, free DPPH radical scavenging activity was 
determined, showing IC50 values of 62 µM and 65 µM for RSV-
nanoemulsions and RSV-CD-nanoemulsions, respectively. RSV-
CD-nanoemulsions displayed a slightly higher IC50 value, which 
could be ascribed to the insertion of RSV molecules into the 
hydrophobic core of CD, which acted as a barrier between RSV 
and DPPH radical.[59] Furthermore, the antioxidant activity of 
core-shell nanoparticles was determined using 2,2´-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid (ABTS) free radical 
scavenging activity assay. The nanoparticles containing both 
polyphenols (RSV and CUR) exhibited higher antioxidant activity 
than single loaded nanoparticles, as expected.[49] 
Free radical scavenging assays with RSV-loaded chitosan 
nanoparticles, exhibited a IC50 of 19 µg/mL with DPPH, a 5 
µg/mL with ABTS and 0.161 mg ferrous sulfate/1 mg de RSV-
lipidic nanoparticles with ferric reducing antioxidant power. 
These results indicated a strong protective effect of the 
formulation against cell oxidative stress damage.[41] 
A synergic effect in the antioxidant activity between CUR 
and RSV was observed through co-encapsulation in 
hyalurosomes made of a synthetic polymer. In this work, the 
percent of DPPH inhibition was 4-fold higher for CUR-RSV-
hyalurosomes than for single loaded ones.[50] 
Furthermore, none of the studied systems modified the 
antioxidant capacity of RSV. 
 
4.1.2. Anticancer activity 
 
The RSV anticancer activity in the works presented here was 
studied in liver, colon, breast and lung cancer cells. In an 
interesting study with very good prospective, lipidic 
nanostructures containing RSV showed a significant inhibition in 
human liver tumor cells (HepG2 cell) growth.[42] 
In comparison, RSV in chitosan nanoparticles and free 
RSV presented equivalent human hepatocellular carcinoma cells 
and human normal hepatocyte cells cytotoxicity, at the same 
concentration. Furthermore, for normal cells, RSV encapsulated 
and pure RSV showed lower cytotoxicity in comparison with Cis-
Pt at above 20 µg/mL.[41] 
Other anti-cancer activity studies were performed in colon 
cancer cell lines, suggested that RSV in MCM-48 was as 
effective as RSV free solution. However, nanoparticles 
substantially decreased intracellular apoptosis protein I 
expression, while control solution showed little impact on this 
process.[53] Additionally, dual encapsulated liposomes (RSV-CD 
inclusion complex-liposomes) showed better anti-proliferative 
properties compared to free RSV, owing to endocytosis and 
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Cytotoxicity experiments were carried out in breast cancer 
cells (MDA-MB 231 cells) and the half maximal inhibitory 
concentration (IC50) for RSV-nanocrystals was 1.25-fold higher 
in comparison to plain RSV within 24 h, which could be due to 
the direct uptake or increased dissolution of RSV-
nanocrystals.[55]  
When micellar casein nanoformulations were used, in vivo 
assay was performed in breast tumor induced in animal groups, 
at the dose of 5 mg/kg per day of RSV up to 3 weeks along with 
free RSV. The tumor volume observed after treatment with free 
RSV and the formulation was 882.6 mm3 and 60.2 mm3, 
respectively (the untreated positive control group had a tumor 
volume of 1433.3 mm3) suggesting excellent antioneoplasic 
effect of the micellar nanosystem. Two tumor growth biomarkers 
(aromatase and factor Kappa-B) were analyzed in order to 
evaluate the in vivo antitumor efficacy of the proposed 
formulation. In this regard, a significant reduction of the 
aromatase biomarker was recorded for the developed 
nanocarrier (15.43 ng/mg tissue protein) in comparison with free 
RSV and with the untreated positive control group (50.85 vs. 
77.14 ng/mg tissue protein). In addition, a significant inhibition of 
nuclear factor Kappa-B factor (NF-κB) was observed in the 
micelles-treated group, compared with free RSV and untreated 
group (1.71, 7.82 and 10.10 ng/mg tissue protein, respectively). 
Moreover, a marker of apoptosis, caspase-3, was also evaluated 
as well, showing that micelles treated group exhibited 2.4 times 
higher caspase-3 level and higher tumor necrosis compared with 
free RSV.[61]  
The in vivo anticancer activity of lignin magnetic 
nanoparticles was studied in Lewis lung carcinoma tumor-
bearing mice. The results showed a significant inhibition in the 
tumor growth compared with RSV alone (82.2 % vs. 21.2 %, 
respectively) and the nanocarrier improved the survival rates on 
the experimental period being 83.3 % against 33.3 % for RSV 
control. These facts were attributed to a RSV sustained release, 
a small particle size and good magnetic properties.[51] 
As a general conclusion, the anticancer performance of 
RSV in the different nanoencapsulation systems tested was 
improved in comparison with RSV in plain solutions. The 
selection of the better system for each application will be related 
to the required form of administration. 
 
4.1.3. Anti-inflammatory activity 
 
ln vitro NF-κB factor inhibition assay was performed measuring 
the green fluorescent protein expression using macrophage NF-
κB reporter cells. The results revealed that encapsulated RSV in 
SPI nanoparticles was stable and its anti-inflammatory 
bioactivity was retained since non-significant modification in the 
green fluorescent protein reduction was obtained as compared 
to free drug.[48] 
Anti-inflammatory studies of RSV in MCM-48 formulation 
on lipopolysaccharide-activated RAW 364.7 cells, showed a 
significant down regulation of NF-κB factor expression in 
comparison with RSV free solution demonstrating improved anti-
inflammatory activity.[53] 
Moreover, the in vitro NF-κB assay showed that RSV 
encapsulation in MCM-48 did not alter its bioactivity and, at 
lower concentration of 5 µg/mL, RSV encapsulation provided 
higher anti-inflammatory activity compared to both RSV 
suspension and solution.[54] 
Finally, in vivo pharmacodynamic study showed that the 
percentage of inhibition in paw oedema from RSV encapsulated 
in niosomal hydrogel, was comparable with a commercial 
formulation (diclofenac Sodium), albeit the former displayed a 
prolonged therapeutic action.[57] 
 It should be noted that the nanoencapsulation of RSV in 
the different systems analyzed did not reduce its anti-
inflammatory activity, but it was improved in some cases. 
 
4.1.4. Physical fatigue 
 
It has been previously demonstrated that supplementation with 
certain antioxidant nutrients could be a practical approach for 
rapid recovery from fatigue and for preventing exercise-induced 
oxidative damage.[64 ] Thus, Yen and co-workers performed a 
pretreatment to rats with a single dose of the RSV-SNEDDS 
before swimming exercise. The effectiveness of the formulation 
was followed by lactate production and clearance test, and blood 
biochemical variables (i.e. plasma ammonia, creatinine 
phosphokinase and glucose). In this study, the lactate 
production did not differ significantly compared with RSV 
solution albeit the pretreatment using RSV-SNEDDS (Capryol™ 
90, Cremophor® EL and Tween 20 (60:35:5 % w/w/w) before 
exercise accelerated the recovery of lactate after exercise (ca. 
1.4 fold faster). Concerning biochemical variables, the plasma 
ammonia level decreased significantly (by 35 %) compared with 
RSV solution associated to less peripherical and central 
fatigue.[65] However, the plasma creatinine phosphokinase and 
the glucose levels showed no differences with respect to RSV 
solution. 
Exhaustive swimming test showed that RSV-SNEDDS 
increased the swimming time to exhaustion of rats ca. 2 times 
compared with RSV solution, confirming that the formulation 
proposed improved not only the RSV bioavailability but also the 
exercise performance of rats. In addition, the formulation 
positively modulated exercise-induced fatigue-related 
parameters.[28] 
 
4.2. Food perspective 
 
4.2.1. Food enrichment 
 
Textural analysis (firmness and adhesiveness parameters) of 
yoghurt enriched with RSV niosomes was performed, comparing 
the results with regular yoghurt as control. RSV Span 60-Dod 
showed similar firmness values compared to the control (i.e. 7.6 
± 0.1 gF vs. 7.5 ± 0.3 gF, respectively). In addition, RSV Mai-
Dod showed adhesiveness very close to control yoghurt (i.e. –
4.17 ± 0.05 gF vs. -4.0 ± 0.5 gF, respectively).[18] 
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In this section, a brief description of the main preparation 
methods mentioned in this review is given. For the sake of clarity, 
the methods are classified depending on the type of confining 




The thin film hydration (TFH) is a simple method and widely 
used to produce vesicles as liposomes, niosomes, among others. 
In this method, the membrane components (non-ionic 
surfactants, phospholipids) are solubilized in an organic solvent. 
Then, a thin film is formed by completely removing the organic 
solvent under vacuum. After that, the dried film is hydrated 
above the transition temperature of the amphiphilic compound, 
using an aqueous solution (buffer solution, water) to obtain 
multilamellar vesicles.[66] In general, further methods are used to 
reduce the size/lamellae of the vesicles such as 
sonication.[17,18,20] extrusion (five times through a 100 nm 
membrane),[58] etc. 
In the direct sonication method the suspension composed 
by the membrane components and the aqueous phase is 
sonicated in an ice bath during several short cycles of high 
intensity, using a probe sonicator,[19, 21, 22] 
In the ethanol injection method (EIM), the membrane 
components are dissolved in ethanol and injected slowly through 
a needle in an aqueous solution maintained at constant 
temperature. Then, the organic solvent is evaporated and during 





5.2.1. Single emulsions 
 
Single emulsions can be prepared using simple methods. Fang 
and co-workers prepared a transparent microemulsion using 
high-pressure homogenization method whereby the resulting 
pre-emulsion is passed through a homogenizator at a pressure 
of 800 bar up to 4 cycles and at 80 °C.[68] Matos and co-workers 
prepared microemulsions by high shear homogenization method 
using high agitation rate in short time (20000 rpm for 1 min).[32] 
In 2017, Kumar and co-workers prepared nanoemulsions 
using ultrasonic emulsification technology.[59] This technique is 
more efficient than other mechanical techniques in terms of 
production cost, handling and maintenance.[ 69 ] The 
nanoemulsion is formed in two steps, firstly the formation of 
primary droplets of the suspension, and then the breakup of 
them by impact of cavitation forces induced by acoustic 
waves.[70,71] 
Besides, nanoemulsions can be prepared using self-
assembly emulsification method, which provides ultralow 
interfacial tensions and large O/W interfacial areas, and thus, 
have high solubilization capacity and thermodynamic stability. 
The method is accomplished using an isotropic mixture of oil, 
surfactant, and co-surfactant to form fine O/W emulsions upon 
introduction into aqueous media under agitation.[35] 
 
5.2.2. Double emulsions 
 
Double emulsions can be prepared by conventional mechanical 
emulsification in two-steps. Thus, Matos and co-workers 
prepared the primary W/O emulsion in glass vessels by high 
shear mixing at 15000 rpm for 10 min. In the next step, the 
primary emulsion was dispersed into the external aqueous 
phase (W2) at 5000 rpm for 2 min to form W1/O/ W2 emulsion.[38] 
The membrane emulsification is another technology used 
to form double emulsions that consists in a drop-by-drop 
emulsification through a microporous membrane. In addition, 
this method allows the production of uniform particles with 
controlled droplets size, low shear stress and energy 
requirement.[ 72 ] Matos and co-workers produced food-grade 
double emulsion using tubular membranes in the cross-flow 
system and a glass membrane with a nominal 10 µm-pore 
diameter.[36] In this experimental design (Figure 27), the 
continuous phase flows through the membrane internal channel, 
and oil droplets are detached from the membrane surface 
forming the emulsion, which is recirculated to the continuous 
phase reservoir. The continuous and dispersed phases are 




Figure 27. Schematic diagram of the A) membrane emulsification unit and B) 





5.3.1. Lipidic particles 
 
Lipidic particles consist of a solid hydrophobic core stabilized by 
a hydrophilic layer of surfactant molecules or polymers, as was 
previously mentioned. The solid dispersion can be prepared by 
hot melt method, where the lipidic material is heated at or above 
the melting point and then cooled rapidly. This process leads to 
form fine solid particles by supersaturation.[73] In 2017, Chang 
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using this method.[46] Scalia and co-workers prepared 
microparticles combining the hot-melt method with sonication (at 
20 kHz for 5 min) and lyophilization, to obtain water-free 
microparticles.[39] On the other hand, nanoparticles could be 
prepared using additionally high pressure homogenization,[41] 
sonication[44] or ultrasonication.[42] 
Solid lipid based nanoparticles (SLNs) can also be 
prepared by solvent injection whereby the lipidic components 
are dissolved in ethanol at 40 °C and injected into the aqueous 
phase containing the surfactant at the same temperature. The 
resulted dispersion is filtered, centrifugated and washed in 
deionized water. The recovered nanoparticles are re-suspended, 
frozen and freeze-dried to obtain the SLNs.[43] 
 
5.3.2. Proteic particles 
 
Koga and co-workers fabricated microparticles made of sodium 
caseinate using the spray drying method.[47] In general, in this 
method, the formulation components are dissolved into a solvent 
and the fine solid particles generated by atomizing the solution 
into a drying process.[73] 
In 2018, Liu and co-workers developed nanoparticles 
based on protein-polyphenol conjugates by the anti-solvent 
precipitation method. Here, zein-epigallocatechin gallate:RSV 
were dissolved in ethanol and added in an aqueous solution 
containing the biosurfactant. Finally, the ethanol in the colloidal 
dispersion formed was removed using a rotary evaporator and 
the same volume of water was added to compensate the lost of 
organic solvent.[49] A similar experimental procedure was 





Lipid-core nanocapsules are a specific type of nanocapsules 
composed of an oily core surrounded by a polymeric shell 
stabilized by surfactant in aqueous medium. Friedrich and co-
workers used the precipitation method of preformed polymer, 
where the oily core is dissolved in acetone at 40 °C and injected 
in the aqueous phase containing the surfactant under moderate 
stirring. Subsequently, the organic solvent is evaporated and the 
aqueous phase is concentrated under reduced pressure to a 
final volume.[52] 
 
5.5. Mesoporous silica nanoparticles 
 
Summerlin and Juère prepared mesoporous silica nanoparticles 
based on Stöber method in presence of a surface-active 
molecule. In this bottom-up synthesis, the tetraethylorthosilicate 
is used as a silica source, the surfactant and the polymer act as 
structure-directing and dispersion agent, respectively. Briefly, 
the surfactant and the polymer are dissolved in a mixture of 
ethanol and ammonium hydroxide. Then, tetraethylorthosilicate 
is added and the mixture stirred. After that, the mixture is 
centrifugated and the solid is washed and dried at high 





Singh and co-workers prepared t-RSV nanocrystals using probe 
sonication. Shortly, the drug is dispersed in an aqueous phase 
containing the stabilizers and stirred to homogenization. Further, 
the sample is sonicated for different time intervals in an ice bath. 
Then, the sample is pre-frozen and lyophilized.[55] 
 Sinico and co-workers used wet media milling technique to 
prepare RSV nanocrystals.[56] Briefly, RSV dried powder is mixed 
with an aqueous solution containing stabilizers and 
subsequently, a mechanical energy is applied to physically 
break down coarse particles to smaller ones.[74] In the work of 
Sinico and co-workers, the authors used sieving to separate 
milling beads (composed by yttrium-stabilized zirconia-silica) 
from nanocrystals.[56] 
 
Summary and Outlook 
 
In this review, we have summarized the most representative 
delivery systems developed for RSV during the last 5 years. 
These carriers have been designed with the aim to overcome 
some of the limitations derived from the low aqueous solubility, 
intestinal permeation, bioavailability, and photostability of RSV. 
The developed delivery systems included liquid formulations 
involving e.g. vesicles, emulsions and nanocapsules, as well as 
solid formulations based on e.g. mesoporous silica nanoparticles 
and nanocrystals. Combinations of both types of systems have 
also been explored for nutritional and pharmaceutical 
applications.  
In the case of RSV-containing vesicles, most studies have 
demonstrated that the mean size, distribution, encapsulation 
efficiency, and stability are determined by the preparation 
method rather than by the chemical composition of the vesicles. 
In terms of administration routes in the pharmaceutical field, the 
incorporation of penetration enhancers in vesicle-based 
formulations constitutes a common strategy for topical 
administration. In addition, RSV-containing liposomes have been 
explored for the treatment of different diseases, via oral 
administration, associated with inflammation and oxidative 
stress in tumour cells. Other carriers such as surface-modified 
nanoparticles, vesicles-in-hydrogels, nanocapsules (for topical 
administration) and emulsions (for oral administration) 
containing inhibitory excipients have also been developed with 
the aims of enhancing the RSV bioavailability and antioxidant 
effects. Furthermore, dual encapsulation strategies such as the 
inclusion of cyclodextrins into liposomes or nanoemulsions allow 
an increase of the RSV loading, compared to conventional 
vesicles. In this case, surface modifications could be performed 
to upgrade the in vivo performance of the system, e.g. cell-
specific targeting, cellular uptake or clearance. Another 
promising dual strategy is the incorporation of RSV-containing 
vesicles (e.g. niosomes) into hydrogel formulations, which 
increases the bioavailability of RSV and provides higher 
resistance and tuneable drug delivery due to the mechanical and 
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The higher efficiency achieved with most of the 
aforementioned systems is related to the enhanced aqueous 
solubility of RSV. Other disadvantages of RSV such as low 
photostability have been addressed using biopolymer-based 
self-nanoemulsifying delivery systems.  
Despite the growing number of publications in this area 
during the last years, and the promising applications of RSV-
containing carriers in pharmaceutical and food industries, more 
research is still necessary for a better understanding of barrier 
penetration mechanisms of RSV, the impact of food matrices on 
the stability and controlled delivery of RSV, as well as the 
pharmacodynamics of the proposed formulations. In addition, 
those studies should also consider the necessity of preserving 
the structural integrity of the carriers in biological fluids while 
retaining the antioxidant capacity of RSV. In this context, the 
development of combined delivery systems and the generation 
of larger number of in vivo data should guide future research in 
this area. 
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  This review summarizes the advances 
and main features of several RSV 
carriers, designed to overcome some 
of its adverse properties, as low 
solubility, low oral bioavailability and 
chemical instability. Formulations of 
different nature were developed and, 
in this way, it was achieved improved 
performance of RSV for potential 
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